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Hypertension has long been recognized as one of the
principal risk factors for cardiovascular disease. It may be
associated with impaired fibrinolysis [1]. Antihypertensive
agents that decrease blood pressure (BP) have been shown
to be effective in reducing cardiovascular morbidity and
mortality [2]. In patients suffering from cardiovascular
events, impaired fibrinolysis is known to be a poor
prognostic factor [3]. However, agents previously used to
treat hypertension, such as diuretics and `-blockers,
have adverse effects on lipid, carbohydrate metabolism,
and fibrinolysis, perhaps counteracting the beneficial
antihypertensive effect [1].
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Antihypertensive agents may modulate fibrinolysis in addition to reducing blood pressure. We conducted
a randomized trial to assess the effects of lercanidipine and losartan on blood pressure (BP) lowering and
three fibrinolytic parameters: plasminogen activator inhibitor-1 (PAI-1), D-dimer, and fibrinogen. All
patients enrolled had essential hypertension and underwent a placebo run-in period of 2 weeks before
randomization to either lercanidipine tablets 10–20 mg once daily or losartan tablets 50–100 mg once daily.
Twenty-six patients completed this study. After 8 weeks of treatment, both groups of patients had
significantly reduced systolic (SBP) and diastolic BP (DBP) (SBP, p = 0.034 and 0.050, respectively; DBP,
p = 0.018 and 0.034 for lercanidipine and losartan, respectively). Both drugs were well tolerated. Only in the
group treated with lercanidipine was PAI-1 concentration significantly reduced (57.1 ( 4.7 to 43.1 ( 4.8 ng/
mL, p = 0.047). No difference was found with D-dimer and fibrinogen in either group. This study shows that
both lercanidipine and losartan are effective antihypertensive drugs in patients with essential hypertension.
Lercanidipine may provide additional benefit in fibrinolysis.
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The activity of the renin-angiotensin-aldosterone axis
can influence endothelial function and endogenous
fibrinolysis. The first angiotensin receptor blocker (ARB)
introduced for clinical use was losartan. Some evidence
suggests that ARB increases fibrinolysis, but these data are
inconsistent [4,5]. Calcium channel blockers (CCBs) are a
heterogeneous group of pharmacologic agents commonly
prescribed to patients with hypertension and coronary
heart disease. Previous studies investigated the impact of
CCBs on fibrinolytic activity with conflicting results [6,7].
Later, lercanidipine was introduced as a treatment. It is a
vasoselective dihydropyridine CCB that causes systemic
vasodilation by blocking the influx of calcium ions through
L-type calcium channels in cell membranes [8]. It is a highly
lipophilic drug, the action of which has a slower onset and
longer duration than other calcium channel antagonists.
Furthermore, lercanidipine may have antiatherogenic
activity unrelated to its antihypertensive and antioxidant
effect [8,9]. However, the effects of lercanidipine on
fibrinolysis have not been studied.
© 2006 Elsevier. All rights reserved.
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This study investigates the antihypertensive efficacy
and safety of lercanidipine and losartan administered orally
once daily for 8 weeks to hypertensive Taiwanese patients.
We also tested the change of the three fibrinolytic parameters:
plasminogen activator inhibitor-1 (PAI-1), D-dimer, and
fibrinogen.
PATIENTS AND METHODS
This was a single-center, randomized, parallel-group study
comparing the efficacy and safety of lercanidipine and
losartan for the treatment of essential hypertension. The
investigators were blinded to the treatment groups. The
study was approved by the institutional review committee
at Kaohsiung Medical University Hospital. Inclusion criteria
included: 1) age older than 18 years; 2) baseline BP over
140/90 mmHg; and 3) willingness to participate in the trial
and to sign a written consent. Those who met these criteria
were excluded if any of the following was present: 1)
secondary hypertension; 2) pregnancy or breast-feeding; 3)
history of myocardial infarction, cerebrovascular disease,
or congestive heart failure; 4) chronic renal insufficiency
(creatinine more than 2 mg/dL); 5) impaired liver function
(aspartate transaminase or alanine transaminase greater
than twice the upper normal limit); 6) history of CCB or
ARB allergy;  and 7) other major medical abnormalities
(e.g. severe drug allergy, autoimmune disease).
Every visit included a physical examination and BP
measurement. All BPs were measured with a mercury
sphygmomanometer while sitting. Upon arrival, after a
10-minute rest, the BP was measured twice, with the second
reading after a 1- to 2-minute interval. The mean was
recorded. Twelve-lead electrocardiography and chest
X-ray were taken to exclude significant organic heart disease.
Systolic BP (SPB) response rate was defined as the percentage
of patients at the end of the study with SBP less than
140 mmHg or a reduction from baseline in SBP by at least
20 mmHg.
Total duration of this trial was 10 weeks (i.e. 2 weeks
washout plus 8 weeks of treatment). During the 2-week
washout (placebo run-in) period, each subject discontinued
all antihypertensive medicines. Eligible patients were then
randomized to one of the following parallel treatment
groups: lercanidipine 10 mg or losartan 50 mg. The initial
4 weeks served as a titration period, during which we
adjusted the dose to achieve the best antihypertensive
effect. Patients with a mean SBP greater than 140 mmHg at
that time were advanced to the double-strength regimen
(lercanidipine 20 mg or losartan 100 mg). At each visit,
general open-ended questions were asked to monitor any
occurrences of adverse events. During the routine visit at
the 6th and 10th weeks, unused medication was counted
and recorded to assure dosage compliance.
Laboratory evaluation was done at screening and at the
end of the study. Fasting blood samples (8-hour fast) were
collected for hematology and biochemistry analysis. Whole
blood (10 mL) was collected in sodium citrate tubes and
centrifuged for fibrinolytic parameters. Plasma was frozen
under –80$C until use. All fibrinolytic parameter analysis
was done at the end of the study. PAI-1 was measured using
the commercial enzyme-linked immunosorbent assay
method (Diagnostica Stago, France). Fibrinogen was
measured according to the Clauss clotting method,
and D-dimer concentration was measured by the
immunoturbidimetric method (Diagnostica Stago).
The primary endpoint of this study was efficacy of BP
lowering after 8 weeks with either lercanidipine or losartan
treatment. The secondary endpoints were the treatment
safety profile and change of fibrinolytic parameters (PAI-1,
D-dimer, and fibrinogen).
Statistical analysis
All data were expressed as mean ( standard error of the
mean. All tests were two-sided. A p value of less than 0.05
was considered statistically significant. r2 test and Wilcoxon
rank-sum test were used to compare categorical data and
nonparametric data, respectively. The t test was used for
analysis between continuous variables. Serial data for
repeated measures were analyzed using two-way analysis
of variance. The Statistical Package for the Social Sciences
(SPSS) 11.0 for Windows (SPSS Inc, Chicago, IL, USA) was
used for statistical analysis.
RESULTS
Baseline data
A total of 35 prospective participants were screened, six
were excluded, and 29 (18 in the lercanidipine and 11 in the
losartan group) were randomized. Exclusion causes were
withdrawal of consent (n = 1) and loss of follow-up after
screening (n = 5). The study was terminated early for three
participants because of intolerance to adverse effects, and
26 completed the trial (16 lercanidipine, 10 losartan). Effects
causing participants to withdraw early on lercanidipine
were dermatitis (n = 1) and palpitations (n = 1). The
unfavorable losartan side effect was rhinitis (n = 1).
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The baseline characteristics of the 29 participants are
given in Table 1. There was no difference between patients
taking lercanidipine and losartan with respect to gender,
age, body weight, biochemical data, and baseline BP.
Blood pressure
Both treatments significantly reduced BP compared with
baseline (Figure 1). The percentage of initial stage 1 and
stage 2 hypertension was 22% and 78% in the lercanidipine
group, and 36% and 64% in the losartan group (p = 0.408).
A total of 11 patients (62%) in the lercanidipine group and
5 (46%) patients in the losartan group were advanced to the
double-strength regimen. The average final doses were
lercanidipine 16.1 ( 1.2 mg and losartan 72.7 ( 7.9 mg. SBP
decreased in patients taking lercanidipine from 161.7 ( 3.4
to 148.4 ( 4.0 mmHg (p = 0.034). Diastolic BP (DBP) dropped
from 99.4 ( 1.4 to 93.8 ( 1.9 mmHg (p = 0.018). In the losartan
group SBP decreased from 160.0 ( 3.5 to 149.7 ( 5.2 mmHg
(p = 0.050) and DBP from 100.1 (  1.8 to 91.9 ( 4.1 mm Hg
(p = 0.034). There was no difference in SBP or DBP reduction
between groups (–13.3 ( 5.5 vs –10.3 ( 4.9 mm Hg for SBP
reduction, p = 0.712, and –5.6 ( 2.1 vs –8.2 ( 3.3 mm Hg for
DBP reduction, p = 0.504).
After 8 weeks of treatment, the response rate was
58.82% in the lercanidipine group (95% confidence interval
[CI]: 32.9–81.6%) and 80% in the losartan group (95% CI:
44.4–97.5%, p = 0.451 between the two groups). Mean
compliance was satisfactory in both groups: 93.0% in the
lercanidipine group and 100% in the losartan group.
Safety
Adverse events were defined as treatment-related adverse
events (i.e. events that first occurred or worsened after
randomization). There was no statistically significant
difference in occurrence of adverse events between the two
groups (lercanidipine 50.0%; losartan 45.5%; p = 1.000) or in
the nature of each adverse event. The most commonly
reported treatment-related adverse events were palpitation
(lercanidipine 16.7%), dizziness (lercanidipine 5.6%, losartan
18.2%), and rhinitis (lercanidipine 5.6%, losartan 18.2%)
(Table 2).
Fibrinolytic parameters
Of the 26 patients who completed the trial, one in the
lercanidipine group did not have an adequate amount of
blood for fibrinolytic parameter analysis. The remaining 25
Table 1. Baseline characteristics of study participants
Lercanidipine Losartan
p
(n = 18) (n = 11)
Age (yr) 51.4 ( 1.5 52.6 ( 2.2 0.740
Sex (male, %) 56 54 1.000
Weight (kg) 66.5 ( 2.5 66.4 ( 3.9 0.805
Fasting blood glucose (mg/dL) 99.7 ( 3.3 99.5 ( 2.3 0.840
Blood urea nitrogen (mg/dL) 13.0 ( 0.7 12.7 ( 0.6 0.822
Creatinine (mg/dL) 0.98 ( 0.05 1.04 ( 0.06 0.380
Cholesterol (mg/dL) 203.0 ( 10.2 191.0 ( 9.2 0.669
Triglyceride (mg/dL) 163.2 ( 19.6 150.1 ( 15.5 0.702
Systolic blood pressure (mmHg) 161.7 ( 3.4 160.0 ( 3.5 0.842
Diastolic blood pressure (mmHg) 99.4 ( 1.4 100.1 ( 1.8 0.912
Figure 1. Systolic and diastolic blood pressure after 8 weeks of  treatment
with lercanidipine and losartan. Numbers within the bars indicate the
blood pressure level in mmHg.
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patients (15 in the lercanidipine group and 10 in the losartan
group) had blood collected for fibrinolytic evaluation. PAI-1
was significantly decreased with lercanidipine (57.1 ( 4.3 vs
43.8 ( 4.6 ng/mL, p = 0.047), but not losartan (66.0 ( 6.4 vs
60.5 ( 6.0 ng/mL, p = 0.284). There was no change in either
group of D-dimer (0.45 (  0.08 vs 0.41 (  0.05 +g/mL,
p = 0.724 in the lercanidipine group; 0.45 (  0.11 vs 0.55 (
0.24 +g/mL, p = 0.893 in the losartan group) or fibrinogen
(2.29 ( 0.14 vs 2.58 ( 0.20 g/L, p = 0.570 in the lercanidipine
group; 2.58 ( 0.13 vs 2.55 ( 0.23 g/L, p = 0.959 in the losartan
group) (Figures 2 and 3).
DISCUSSION
This study had three findings. First, in Taiwanese patients,
essential hypertension treatment with both lercanidipine
and losartan were shown to be comparably effective in
Figure 3. Fibrinolytic parameters after 8 weeks of treatment with losartan.
Figure 2. Fibrinolytic parameters after 8 weeks of  treatment with lercanidipine.
Table 2. Reported adverse effects
Lercanidipine Lorsartan
p
(n = 18) (n = 11)
All adverse events 9 (50.0) 5 (45.5) 1.000
Palpitation 3 (16.7) 0 (0.0) 0.269
Dizziness 1 (5.6) 2 (18.2) 0.539
Rhinitis 1 (5.6) 2 (18.2) 0.539
Sleep problems 2 (11.1) 0 (0.0) 0.512
Chest pain 1 (5.6) 1 (9.1) 1.000
Dyspnea 1 (5.6) 1 (9.1) 1.000
Arthralgia 1 (5.6) 0 (0.0) 1.000
Bronchitis 1 (5.6) 0 (0.0) 1.000
Constipation 1 (5.6) 0 (0.0) 1.000
Dermatitis 1 (5.6) 0 (0.0) 1.000
Cough 0 (0.0) 1 (9.1) 0.379
Headache 0 (0.0) 1 (9.1) 0.379
Neck rigidity 0 (0.0) 1 (9.1) 0.379
Vertigo 0 (0.0) 1 (9.1) 0.379
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lowering BP. Second, both treatments were well tolerated
and had a low withdrawal rate. Third, treatment with
lercanidipine may provide additional beneficial effects on
fibrinolysis.
CCBs are widely used for the treatment of hypertension
and prevention of cardiovascular disease [10]. Some studies
suggest that mechanisms in addition to BP control may be
important in determining the therapeutic efficacy of CCBs
[11]. Many CCBs have been reported to have a potential
antiatherogenic effect unrelated to their antihypertensive
activity. Lercanidipine has been reported to inhibit arterial
smooth muscle cell proliferation and migration [12], to
reduce the extent of atherosclerotic lesions [13], to have
antioxidant activity and significant reduction of low-density
lipoprotein cholesterol oxidation,  and to restore endothelial
function [9,14]. For the first time, our study shows that
lercanidipine may have beneficial effects on fibrinolysis.
Impairment of fibrinolysis is instrumental in promoting
atherothrombotic events in patients with hypertension.
Therefore, several studies have evaluated the impact of
CCBs on fibrinolytic activity, but results are conflicting
[6,7]. Mechanisms for such an effect are unknown, although
a direct action of lercanidipine on vascular endothelium
probably plays an important role. Lercanidipine has been
suggested to improve endothelial function, mainly by
restoring nitric oxide availability and preventing
hyperpolarization, an effect probably determined by
antioxidant activity [14]. Because PAI-1 is synthesized in the
vascular endothelium, and endothelial dysfunction induces
an imbalance in fibrinolysis, the improvement of endothelial
function might reverse the fibrinolytic imbalance.
     Angiotensin II leads to expression of PAI-1 in cell culture
by stimulating the tissue factor (TF). This effect is mediated
by the angiotensin II type 1 (AT1) receptor [15,16]. Inhibition
of angiotensin-converting enzyme activity attenuates the
increase in PAI-1 mRNA and plasma activity in diabetic
mice with cardiac TF, and AT1 receptor blockade reduces
PAI-1 and TF activities in cell culture and animal studies
[16,17]. Losartan was the first ARB, having been introduced
in the treatment of hypertension in 1995. In 20 patients with
moderate hypertension, 4 weeks of treatment with losartan
had no effect on PAI-1 antigen, either during basal conditions
or during acute hyperinsulinemia induced by oral glucose
or insulin infusion [4]. In another larger study, irbesartan
and candesartan, but not losartan, significantly lowered
plasma levels of PAI-1 antigen [7]. As with the present
study, there was no significant change in PAI-1, D-dimer, or
fibrinogen after 8 weeks of losartan treatment. Apparently,
different ARBs have differing fibrinolysis potency.
Therefore, more work is necessary to clarify effects of
various ARBs on fibrinolytic parameters.
Extrapolating efficacy and tolerability data from one
patient population to another has major limitations,
particularly when different ethnic groups are involved [18].
Losartan usage in Chinese populations was previously
reported to be well tolerated and to significantly reduce SBP
and DBP after 4–8 weeks’ treatment [19]. This, however, is
the first study to examine the relative efficacy and tolerability
of lercanidipine in Chinese hypertensive populations.
Lercanidipine was effective and well tolerated. We found
that once-daily, 8-week treatment with lercanidipine
achieved a significant reduction in SBP and DBP, and was
as effective in lowering BP as a once-daily treatment of the
same duration with losartan. Patients had satisfactory
compliance and response rate.
There were three limitations in our study. First, our
investigation involved only a small number of patients.
Second, we had no placebo group because of ethical issues.
Therefore, we administered lorsartan, which was known to
be effective against hypertension but to have a neutral effect
on fibrinolysis [4], to the control group. Third, although the
change in PAI-1 may have reached statistical significance, it
was unclear if this was clinically meaningful.
CONCLUSIONS
Both lercanidipine and losartan given once daily are effective
and well-tolerated antihypertensive agents in Taiwanese
patients with essential hypertension. Eight weeks of
treatment with lercanidipine also significantly reduced
PAI-1. This effect may provide additional cardiovascular
benefit, but it requires confirmation from more extensive
clinical data.
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